Opportunities and Challenges Associated with Developing Additional Indications for Clinical Development Candidates and Marketed Drugs

Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs

Volumn , Issue , 2012, Pages 33-51

  Frail, Donald E ^a   Barratt, Michael J ^b  

^a ASTRAZENECA   (United Kingdom)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Effective drug repositioning, real risks and mitigation; Marketed drugs, additional indications and strategies used; Marketed drugs, indications and challenges

Indexed keywords

EID: 84886565873     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118274408.ch2     Document Type: Chapter

References (24)

1. Gelijns, A.C., Rosenberg, N., Moskowitz, A.J. (1998). Capturing the unexpected benefits of medical benefits. The New England Journal of Medicine, 339, 693 - 698.
2. Graul, A.I., Sorbera, L., Pina, P., Tell, M., Cruces, E., Rosa, E., Stringer, M., Castañer, R., Revel, L. (2010). The year ' s new drugs & biologics - 2009. D rug News Perspect, 23 (1), 7 - 36.
3. Bell, A. The Viagra ® Story: From Laboratory to Clinical Discovery. http://www. mbcfoundation.org/pdfs/Blockbuster%20Drug%20Symposium%20Final.pdf.
4. Wang, C., Takeuchi, K., Pinto, L.H., Lamb, R.A. (1993). Ion channel activity of influenza A virus M2 protein: Characterization of the amantadine block. Journal of Virology, 67 (9), 5585 - 5594.
5. Verma, U., Sharma, R., Gupta, P., Kapoor, B., Bano, G., Sawhney, V. (2005). New uses for old drugs: Novel therapeutic options. Indian Journal of Pharmacology, 37 (5), 279 - 287.
6. Mekdeci, B. How a Commonly Used Drug Caused Birth Defects. http://www. birthdefects.org/research/bendectin_1.php.
7. Teo, S.K., Stirling, D.I., Zeldis, J.B. (2005). Thalidomide as a novel therapeutic agent: New uses for an old product. Drug Discovery Today, 10 (2), 107 - 114.
8. Celgene Corporation. http://www.thalomid.com/thalomid_history.aspx
9. Allergan, Inc. http://www.restasis.com/default.htm?x=Restasis
10. Hathaway, C., Manthei, J., Scherer, C. (2009). Exclusivity strategies in the United States and European Union. Update (Loma Linda University. Ethics Center), 3 (May - June), 34 - 39.
11. Pugatch, M.P. (2004). Intellectual Property and Pharmaceutical Data Exclusivity in the Context of Innovation and Market Access. http://www.iprsonline.org/ unctadictsd/bellagio/docs/Pugatch_Bellagio3.pdf
12. Kesselheim, A.S., Solomon, D.H. (2010). Incentives for drug development - The curious case of colchicine. The New England Journal of Medicine, 362, 2045 - 2047.
13. Grabowski, H., Long, G., Mortimer, R. (2011). Data exclusivity for biologics. Nature Reviews. Drug Discovery, 10, 15 - 16.
14. Wikipedia. http://en.wikipedia.org/wiki/Orphan_drug
15. Official Journal of the European Communities (1999). http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf
16. Masuda, S. (2008). The market exclusivity period for new drugs in Japan: Overview of intellectual property protection and related regulations. Journal of Generic Medicines, 5 (2), 121 - 130.
17. U.S. Food and Drug Administration (1992). How to Apply for Designation as an Orphan Product. http://www.fda.gov/ForIndustry/DevelopingProductsforRare DiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm135122.htm
18. U.S. Food and Drug Administration. Search Orphan Drug Designations and Approvals. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm
19. European Medicines Agency. Rare Disease (Orphan) Designations. http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan_search.jsp & murl=menus/medicines/medicines.jsp & mid=WC0b01ac058001d12b
20. Lipinski, C.A., et al. (1980). Bronchodilator and antiulcer phenoxypyrimidinones. Journal of Medicinal Chemistry, 23, 1026 - 1031.
21. Reaume, A., Saporito, M.S. Methods and formulation for modulating lyn kinase activity and treating related disorders, USPTO, Patent Number: 7,776,870 2010.
22. Melior Discovery Press Release (2009). http://www.meliordiscovery.com. Melior Discovery Announces IND Approval for Novel Diabetes Drug MLR1023. Press release.
23. Department of Health, Medicines, Pharmacy & Industry Group, United Kingdom (2011). A New Value - Based Approach to the Pricing of Branded Medicines. http:// www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/ dh_128404.pdf
24. Jack, A. (2001). Setback for off - label use of Roche drug. Financial Times, http://www.ft.com/cms/s/0/82afcb50 - d536 - 11e0 - bd7e - 00144feab49a.html?ftcamp= rss#axzz1X70hNSuP. Sept. 2 2011.